glp-1/gip/glucagon triple agonist The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review retatrutide phase 3 2025 triple

doi: 10.1097/mjt.0000000000001196 37 LeeC

:

Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges

We are direct about the limits of the evidence

In The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease (pp

Da xn mu, thm sm, m nu